NRC and FDA Regulations Affecting Nuclear Pharmacy Practice

Abstract

Radiopharmaceuticals are radioactive drugs that are used in nuclear medicine practice for diagnosis and treatment of disease. Nuclear pharmacy practice is a patient-oriented pharmaceutical service that promotes the safe and efficacious use of radiopharmaceuticals and other drugs used in nuclear medicine, and is regulated jointly by a variety of federal, state, and local agencies. Given that the medical use of radiopharmaceuticals is highly regulated at multiple levels of government, it is not surprising that nuclear pharmacy practice is conducted in a complex regulatory environment. The purpose of this article is to provide a brief overview of this regulatory environment, primarily in terms of two important regulatory agencies involved (Nuclear Regulatory Commission and Food and Drug Administration), their primary authority and activities, and the regulations that must be satisfied in order to assure the safe and efficacious use of radiopharmaceuticals.

Get full access to this article

View all access options for this article.

References

Nuclear Pharmacy Practice Standards : American Pharmaceutical Association, Washington, DC, 1984

Meyers EL : Radiopharmaceuticals: Regulatory problems, in Subramanian G, Rhodes BA, Cooper J, et al (eds): Radiopharmaceuticals. New York, NY, Society of Nuclear Medicine, 1975, pp 259-263

Food and Drug Administration : Radioactive new drugs for investigational use. Fed Reg 28:183, January 8, 1963

Food and Drug Administration : Radioactive new drugs: New-drug application requirements. Fed Reg 36: 21026, November 3, 1971

Halperin JA , Stringer SA , Eastep RD : Regulation of radiopharmaceuticals: Analysis of radiopharmaceuticals approved for marketing in the United States 1951-1978, in: Radiopharmaceuticals II, Proceedings of the Second International Symposium on Radiopharmaceuticals . New York, NY, Society of Nuclear Medicine, 1979, p xxi

Food and Drug Administration : Radioactive new drugs and radioactive biologics. Termination of exemptions . Fed Reg 40:31298, July 25, 1975

Vandergrift, JF : Regulatory problems in nuclear medicine, in Hladik WB , Saha GB , Study KT (eds): Essentials of Nuclear Medicine Science. Baltimore, MD, Williams & Wilkins, 1987, pp 321-330

Kowalsky RJ , Perry JR : Licensing, regulatory control and radiation safety, in: Radiopharmaceuticals in Nuclear Medicine Practice. Norwalk, CT, Appleton & Lange, 1987, pp 473-500

Chilton HM , Witcofski RL : Regulations affecting radiopharmaceuticals, in: Nuclear Pharmacy: An Introduction to the Clinical Application of Radiopharmaceuticals . Philadelphia, PA, Lea & Febiger , 1986, pp 150-157

10.

Nuclear Regulatory Commission : Regulation of medical uses of radioisotopes. Statement of general policy. Fed Reg 44:8242, February 9, 1979

11.

Guide for the preparation of applications for medical use programs: Regulatory Guide 10.8 (Task FC 415-4), Revision 2. Washington, DC, Nuclear Regulatory Commission, August 1987

12.

Fink JL , Marquardt KW , Simonsmeier IM (eds): Pharmacy Law Digest, Facts and Comparisons. Philadelphia, PA, Lippincott, 1987 , pp DC-19

13.

Levine G. , Massetti C. , Malhi B. : A methodology for preparing pediatric doses of 99mTc MAA for pulmonary perfusion studies. J Nucl Med Technol 8:94-96, 1980

14.

Siegel BA : Radiopharmaceuticals and FDA: A clinician's perspective. J Nucl Med Technol 11:177-186,1983

15.

Nuclear Pharmacy Guideline : Criteria for determining when to register as a drug establishment, Division of Drug Labeling and Compliance (HFN-310). Washington, DC, Center for Drugs and Biologics, Food & Drug Administration, May 1984